HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

HUTCHMED (China) LimitedNASDAQ: HCM

Operating Expenses · Q2 FY2025 · quarter ended Jun 2025

Operating expenses dips below year-ago levels

Q2 FY2025 operating expenses of $56.81M fell 25.8% year over year, behind the +0.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -20.0% a year.

Context

  • Operating expenses amounted to 48.6% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.8% toward the trailing-twelve-month pace of +0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2025
$56.81M+0.0% QoQ
Last fiscal yearDec 2025
$267.45M-16.9% YoY
LTMJun 2025
$73.46M+0.2% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.8%——
1 year-16.9%——
3-year CAGR-20.0%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
267.45M USD
Year-over-year change
-16.9%
4-year CAGR
-11.0%

Operating Expenses vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.2% is the 5th highest of 9, against a peer median of +0.3%.
  • Operating expenses amounts to 12.2% of revenue for HCM, versus a peer median of 93.9%.
HCM Competitors
Operating Expenses for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€3.77B EUR+18.8%+18.2%142.6%
INCYIncyte CorporationLTM Jun 2026$3.55B USD+8.1%+9.7%61.0%
GMABGenmab A/SLTM Jun 2026$2.51B USD—-36.0%60.7%
AAPGAscentage Pharma Group InternationalFY2025CN¥1.61B CNY+21.5%+15.7%287.6%
EXELExelixis, Inc.LTM Jul 2026$1.38B USD-5.2%+0.3%56.6%
LEGNLegend Biotech CorporationLTM Sep 2026$740.02M USD-0.1%+14.3%54.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026$596M USD-0.7%+16.7%509.4%
ZLABZai Lab LimitedLTM Jun 2026$517.9M USD+0.8%-3.3%115.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$163.78M USD-44.2%+49.7%72.7%
HCMHUTCHMED (China) LimitedLTM Jun 2025$73.46M USD+0.2%-20.0%12.2%
ANLAdlai Nortye Ltd.LTM Jun 2024$68.58M USD—-15.4%1056.8%
Peer median (excluding HCM) —+0.3%+12.0%93.9%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue356.13M426.41M838M630.2M549.96M
Cost of Revenue258.23M311.1M384.45M348.88M337.24M
Gross Profit97.89M115.31M453.55M281.32M212.72M
Gross Margin27.5%27.0%54.1%44.6%38.7%
Research & Development207.45M267.59M303.06M213.37M164.15M
Selling, General & Admin127.13M136.11M133.18M112.91M103.3M
Operating Expenses426.21M523M436.23M321.93M267.45M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
EBITDA(207.96M)(401.11M)26.58M(31.36M)(41.38M)
EBITDA Margin-58.4%-94.1%3.2%-5.0%-7.5%
Operating Income(328.32M)(409.77M)18.38M(43.71M)(54.73M)
Operating Margin-92.2%-96.1%2.2%-6.9%-10.0%
Interest Income2.08M9.6M36.15M40.08M50.01M
Interest Expense592K652K759K2.87M2.87M
Other Income / Expenses173.19M51.52M87.23M89.07M577.45M
Income Before Tax(155.33M)(360.24M)105.6M45.36M522.72M
Pre-Tax Margin-43.6%-84.5%12.6%7.2%95.0%
Income Tax Expense11.92M(283K)4.51M7.19M63.78M
Net Income(194.65M)(360.84M)100.78M37.73M458.12M
Net Margin-54.7%-84.6%12.0%6.0%83.3%
EPS (Basic)(1.25)(2.15)0.600.222.65
EPS (Diluted)(1.25)(2.15)0.600.222.60
Weighted Avg Shares158.54M169.43M169.93M171.07M171.66M
Weighted Avg Shares (Diluted)158.54M169.43M173.84M174.57M174.58M

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.